한미약품

128940KOSPI의약품 제조업

63.6 / 100

Reference Date: 2026-06-10

Financial Score17.5 / 40

News Sentiment20.1 / 25

Momentum14.0 / 20

Disclosure12.0 / 15

AI Analysis: ROE significantly exceeds the industry average but PER raises overvaluation concerns. Roughly flat over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Hanmi Pharmaceuticals operates in three segments: pharmaceuticals, APIs, and overseas pharmaceuticals. It produces and sells key drugs such as the hypertension treatment 'Amozaltan' and has a global presence through its API division, Hanmi Precision Chemicals, which holds international certifications like FDA. Its overseas subsidiary, Beijing Hanmi, focuses on pediatric medications and hypertension treatments in the Chinese market.

Number of Employees

2,382people

Average Salary

86.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

32.04Industry Average 11.930.0Point

2.7x industry avg (risky)

PBR

3.86Industry Average 0.890.0Point

4.3x industry avg (risky)

ROE

14.05Industry Average 4.017.0Point

3.5x industry avg (excellent)

Debt Ratio

7.70Industry Average 12.435.0Point

Lower than industry avg (good)

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲1.9% (2-year basis)

Operating Profit Growth Rate

2.0 / 3

Avg ▲8.6% (2-year basis)

ROE Trend

2.5 / 4

Avg ROE 13.9% (declining, 3yr)

Detailed News Sentiment

34 totalPositive 29Neutral 3Negative 2Average Sentiment Score 80.3

Positive
한미약품 모녀 백기사 라데팡스, 오스코텍 지배구조 개선 참여
한미약품 모녀의 백기사 라데팡스가 오스코텍의 지배구조 개선에 참여함으로써 경영 안정성이 기대되며, 이는 한미약품에 긍정적 영향을 미칠 것으로 보인다.
Positive
한미약품, 50조 노다지 'MASH 신약' 후속 개발 전략 '셈법' 복...
한미약품의 MASH 신약 후속 개발 전략 발표로 임상 데이터 도출 예정, 상업화 성공 가능성 높아짐.
Positive
[바이오사이언스] K바이오 기술수출 '30조' 시대 당겨질까
한미약품을 포함한 바이오 기업들의 기술 수출이 급증하여 시장에 긍정적 영향을 미치고 있다.

Detailed Momentum

52-week position5.0Point

52w mid range (44%)

Current 428,500Won52-week high 626,00052-week low 270,000

1-month return3.0Point

1m -0.46% (flat)

Volume trend6.0Point

Volume surge

Detailed Disclosure

8 totalPositive 1Neutral 7Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-05
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-01
Neutral기업지배구조보고서공시2026-06-01
Neutral투자판단관련주요경영사항 (소네페글루타이드 (Sonefpeglutide; LAPS GLP2 agonist; HM15912) 기술이전 계약 체결)2026-06-01
Neutral투자판단관련주요경영사항 (HCP18034 개발을 위한 식약처(MFDS) 제3상 임상시험 계획 승인)2026-05-29